Prenumeration
Beskrivning
Land | Finland |
---|---|
Lista | First North Finland |
Sektor | Hälsovård |
Industri | Medicinteknik |
Modulight Corporation Press release October 13, 2022, at 08:00 a.m. EEST
Modulight Corporation will publish its 3Q22 business review on October 20, 2022, approximately at 08:00 a.m. EEST.
Modulight's CEO Seppo Orsila will present the result in an English-language webcast, which will be held on October 20, 2022 at 10:30 a.m. EEST. The broadcast can be followed at https://modulight.videosync.fi/q3-2022-results.
Questions are to be submitted in writing in the webcast portal. CFO Anca Guina will also be present to answer questions.
Presentation materials will be available before the start of the event on the company’s website at www.modulight.com/reports-presentations/
For further information, please contact:
CEO Seppo Orsila, m. +358 40 830 4671
Investor relations: Ulla Haapanen, m. +358 40 830 4676
email: ir@modulight.com
Certified adviser: Danske Bank A/S, Finland Branch, m. +358 40 414 5358
www.modulight.com
Twitter: @modulight
Modulight in brief
Modulight Corporation is a biomedical laser company that designs and manufactures products for oncology, ophthalmology and genetics. The company also provides solutions for selected high value-add applications including quantum computing and digital press. The company’s products include medical devices, subsystems, software, cloud services and specialized semiconductors. Modulight’s products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland. www.modulight.com
Follow Modulight: Twitter | LinkedIn | Facebook | YouTube | Instagram | #killcancer #laserfamily